Physical Capacity Among Patients Treated With Periacetabular Osteotomy for Hip Dysplasia: a Cross-sectional Study

November 8, 2022 updated by: Sally Oppendieck Andersen, Copenhagen University Hospital, Hvidovre
This cross-sectional study investigates the physical capacity of patients, who have undergone a periacetabular osteotomy for hip dysplasia within the last 1-5 years.

Study Overview

Detailed Description

Hip dysplasia is a common disease both worldwide and among the Danish population. The disease is characterized by a shallow and oblique acetabulum, resulting in insufficient coverage of the femoral head. The abnormalities of the dysplastic hip joint lead to altered biomechanical adaptations, highly affecting the physical capacity of patients. Studies have shown that patients with hip dysplasia experience reduced muscle strength and gait abnormalities, when compared to healthy controls.

Each year, approximately 200 Danes with hip dysplasia are treated with periacetabular osteotomy (PAO). As the preferable joint-preserving surgical treatment for younger patients with symptomatic hip dysplasia, the PAO reduces prevalence of muscle-tendon-related pain and improves hip and groin related patient-reported outcome measures (PROMs). By extension, studies report a hip survival rate of approximately 75% 12 years following PAO.

However, little is known about objective measures of physical capacity following PAO. Despite reducing muscle-tendon-related pain and improving PROMs, gait adaptations still remain and studies report no improvements in muscle strength, nor in the physical activity profile, 1 year following treatment with PAO. Thus, the field calls for research aiming to identify parameters of impaired physical capacity in patients treated with PAO. Thorough knowledge of physical capacity in these patients may contribute to the establishment of a science-based rehabilitation strategy, potentially improving physical activity, function, work capacity and quality of life.

The primary aim of this study is to analyse and identify parameters of impaired physical capacity in patients with hip dysplasia 1-5 years following treatment with PAO. Gait function, defined as peak hip extension angle and peak hip flexor moment, is chosen as the primary outcome, due to previously shown correlations between the extent of gait impairments and the Copenhagen Hip and Groin Outcome Score (HAGOS).

As recommended by the International Hip-related Pain Research Network (IHiPRN), measurements of physical capacity in patients with hip-related pain should include: clinical measures, laboratory-based measures, measures of physical activity and return to physical activity. Secondary outcomes of this study are: muscle activity during level walking and walking with inclination, endurance and pain during walking, range of motion (ROM), muscle strength, hip and muscle-tendon-related pain, radiographic measures and PROMs (present level of physical activity and sports & activity level prior to and after treatment with PAO).

We hypothesise that patients with the lowest scores of HAGOS subscales pain and sport/recreation will have the lowest physical capacity, measured as: gait impairments, reduced muscle strength and prevalence of muscle-tendon-related pain.

This is a cross-sectional study.

Thirty subjects from across the country, aged 18-40 years, who have undergone a PAO for hip dysplasia within the last 1-5 years, will be included in the study.

All testing will be performed at Copenhagen University Hospital, Hvidovre.

Study Type

Observational

Enrollment (Actual)

40

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Hvidovre
      • Copenhagen, Hvidovre, Denmark, 2650
        • Department of Orthopedic Surgery, Copenhagen University Hospital Amager-Hvidovre, Hvidovre, Denmark

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 40 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Subjects who have undergone a periacetabular osteotomy (PAO) for hip dysplasia within the last 1-5 years.

Subjects will be recruited through social media from two specific closed-member facebook groups for patients with hip dysplasia. Permission for recruiting through social media was granted by The Danish Data Protection Agency along with permission for the handling of personal data (P-2020-261).

Description

Inclusion Criteria:

  • Age 18 to 40 years
  • BMI < 30
  • Primary diagnosis of ipsilateral or bilateral hip dysplasia
  • Treated with PAO for hip dysplasia unilaterally or bilaterally within 1-5 years

Exclusion Criteria:

  • Retroverted acetabulum (positive posterior wall sign and ischial spine sign) treated with reversed PAO
  • Total Hip Arthroplasty (THA)
  • Pain management with analgesics or other medication affecting muscle function and perception of pain
  • A need for walking aids to be able to walk freely

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Cross-Sectional

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Hip Dysplasia group
Subjects who have undergone a periacetabular osteotomy (PAO) for hip dysplasia within the last 1-5 years.

This cross-sectional study will involve evaluation of physical capacity by assessment of:

  1. Gait function
  2. Muscle activity during walking
  3. Endurance during walking
  4. Hip muscle strength
  5. Hip range of motion
  6. Hip and muscle-tendon-related groin pain
  7. Hip and groin related patient-reported outcome measures (PROMs)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Gait function
Time Frame: Baseline
Peak hip extension angle and peak hip flexor moment
Baseline

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Gait function following fatigue
Time Frame: Baseline
Peak hip extension angle and peak hip flexor moment following a 6-Minute walk test
Baseline
Muscle activity
Time Frame: Baseline
Muscle activity of hip specific muscles during level walking and walking with inclination
Baseline
Maximal voluntary isometric hip muscle force
Time Frame: Baseline
Adduction, abduction, flexion and extension
Baseline
Hip and muscle-tendon-related groin pain
Time Frame: Baseline
FADIR and FABER, modified standardized clinical entity approach
Baseline
Hip specific patient reported outcome measures (PROMs)
Time Frame: Baseline
Present level of physical activity and sports & activity level prior to and after treatment with PAO
Baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Per Hölmich, Professor, dr.med., Sports Orthopedic Research Center - Copenhagen (SORC-C), Copenhagen University Hospital Amager-Hvidovre, Hvidovre, Denmark

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 1, 2020

Primary Completion (Actual)

October 1, 2022

Study Completion (Actual)

November 1, 2022

Study Registration Dates

First Submitted

October 12, 2020

First Submitted That Met QC Criteria

October 12, 2020

First Posted (Actual)

October 19, 2020

Study Record Updates

Last Update Posted (Actual)

November 14, 2022

Last Update Submitted That Met QC Criteria

November 8, 2022

Last Verified

November 1, 2022

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Undecided

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Joint Diseases

Clinical Trials on Testing of physical capacity

3
Subscribe